SOUTH SAN FRANCISCO, Calif.—May 13, 2025 — Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune- mediated diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. "We shared exciting results this quarter from the PORTOLA trial, the first successful randomized study in treatment-refractory AIH," said Chris Kirk, CEO and co-founder of Kezar. "Ther ...